London & Capital Asset Management Ltd Sells 54,736 Shares of Novo Nordisk A/S $NVO

London & Capital Asset Management Ltd trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 45.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 66,848 shares of the company’s stock after selling 54,736 shares during the quarter. London & Capital Asset Management Ltd’s holdings in Novo Nordisk A/S were worth $4,615,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. First Hawaiian Bank boosted its position in shares of Novo Nordisk A/S by 0.6% during the first quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after purchasing an additional 142 shares in the last quarter. Anchor Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 1.1% in the 1st quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after purchasing an additional 150 shares in the last quarter. Werba Rubin Papier Wealth Management boosted its position in shares of Novo Nordisk A/S by 4.1% in the 2nd quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock worth $302,000 after purchasing an additional 173 shares in the last quarter. Atwood & Palmer Inc. grew its stake in shares of Novo Nordisk A/S by 31.8% in the 2nd quarter. Atwood & Palmer Inc. now owns 737 shares of the company’s stock worth $51,000 after buying an additional 178 shares during the last quarter. Finally, Copeland Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after acquiring an additional 186 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NVO shares. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday. Morgan Stanley reissued an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Wednesday, September 17th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a report on Tuesday, November 25th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $56.00.

Novo Nordisk A/S Trading Down 2.3%

Shares of NVO opened at $46.76 on Tuesday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The company has a market cap of $208.80 billion, a P/E ratio of 13.59 and a beta of 0.67. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $112.52. The company’s fifty day simple moving average is $51.61 and its 200-day simple moving average is $58.84.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.